Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
40 hedge funds and large institutions have $11.4M invested in Unity Biotechnology in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 5 closing their positions.
268% more capital invested
Capital invested by funds: $3.1M → $11.4M (+$8.3M)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
75% more call options, than puts
Call options by funds: $480K | Put options by funds: $275K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% more funds holding
Funds holding: 37 → 40 (+3)
0.85% less ownership
Funds ownership: 18.87% → 18.01% (-0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FH
Financial Harvest
Winter Park,
Florida
|
+$371K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$149K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$79.6K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$55.8K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$51.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.02M |
| 2 |
Morgan Stanley
New York
|
-$66.3K |
| 3 |
Squarepoint
New York
|
-$33.1K |
| 4 |
Jane Street
New York
|
-$20.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.15K |
UBX Hedge Fund Activity: Q1 2025 in Review
40 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2025, worth a combined $11.4M — up 268% from $3.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new UBX positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Financial Harvest, opening a new position worth an estimated $371K. The largest seller was Alyeska Investment Group, cutting an estimated $1.02M.
- 40 institutional investors held Unity Biotechnology (UBX) as of Q1 2025, up from 37 in Q4 2024.
- Funds reported $11.4M of Unity Biotechnology stock for Q1 2025, up 268% quarter-over-quarter.
- 8 funds opened new Unity Biotechnology positions in Q1 2025 and 5 closed out, a net change of +3 holders.
- The largest Unity Biotechnology buyer in Q1 2025 was Financial Harvest, an estimated $371K added.
- The largest Unity Biotechnology seller in Q1 2025 was Alyeska Investment Group, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2025.